Mesoblast (MESO) announced that the FDA has granted investigational new drug clearance to directly proceed for a registrational clinical trial evaluating Ryoncil in Duchenne muscular dystrophy, which affects approximately 15,000 children in the U.S.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO:
- Mesoblast reports $30.3M in Ryoncil sales in March quarter
- Mesoblast reports March quarter Ryoncil sales of $30.3M
- Largest borrow rate increases among liquid names
- Mesoblast Grants New Director Options Following 2025 AGM Approvals
- Mesoblast Discloses Director Gregory George’s Share and ADS Purchases in Early March 2026